Search

Boehringer Ingelheim announces nintedanib expanded access program (EAP) for children and adolescents with fibrosing interstitial lung disease

How to Help Prevent Lyme Disease in Your Dog | Boehringer Ingelheim US

Click here to learn more about steps that pet owners can take to help prevent Lyme Disease in dogs.

Boehringer Ingelheim announces InPedILD PhaseIII trial results

Supporting People with Diabetes and Related Conditions in the Time of COVID-19

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

Canine Lyme Disease: What You Need to Know | Boehringer Ingelheim US

Click here to discover all you need to know about lyme disease in dogs; causes, symptoms, prevention, detection and treatment.

Parasiticides

Evolving the Unwearable Collection

Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™

Dr. Wolchinsky Receives Pioneer Award | Boehringer Ingelheim US

Read more about Dr. Steven Wolchinsky receiving the first Vetmedin® (pimobendan) Cardiology Pioneer award, for his work and commitment to animal health.

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.

Update on sNDA for fibrosing ILD in children and adolescents

Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

Are combination therapies the answer to battling KRAS cancers?

Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal

How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health

Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.

Boehringer Ingelheim’s Carine Boustany Appointed to BIO Board

Occupational Health and Safety

Foot & Mouth Disease US Supply Vaccines | Boehringer Ingelheim US

Click here to find out how Boehringer Ingelheim is fighting against foot-and-mouth disease by continuing to supply the US vaccine bank.

FDA accepts sNDA for children/adolescents with fibrosing ILD

U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease

Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

A Brave New World: Digital Health Redo | Boehringer Ingelheim US

Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.

Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers